ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

When Bristol Myers Squibb originally unveiled pivotal data for Breyanzi in second-line large B-cell lymphoma (LBCL) a year ago, a key weak point was a short follow-up time in the study. Now, the New York pharma is cranking up its CAR-T rivalry against Gilead Sciences with updated results.